Camlin Fine Sciences (CAMLINFINE) investor relations material

Executive summary

• Q1 FY27 revenue reached INR 5,199 million, up 28% year-over-year, marking the highest-ever quarterly revenue, but margins declined sharply due to elevated raw material and freight costs and exceptional items related to insurance settlements for fire incidents.

• EBITDA margin dropped to 3.4–4%, with PAT from continuing operations negative at Rs -318 million, reflecting margin pressures and exceptional costs.

• Segmental reporting introduced, dividing business into specialty ingredients, aroma (vanillin), and performance chemicals.

• Unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, were approved by the Board on August 11, 2026.

• Results include impacts from discontinued operations and ongoing restructuring.

Financial highlights

• Specialty ingredient revenue exceeded INR 4,000 million, with blends contributing over INR 3,000 million and straights INR 927 million.

• Aroma segment sold 560 tons of vanillin, with 350 tons of methyl vanillin and 200 tons from channel stocks.

• Performance chemicals EBITDA at 1.5% due to diphenol plant shutdown and high raw material costs.

• Adjusted EBITDA stood at Rs 176 million, margin at 3.4% vs 5.0% YoY.

• Consolidated net loss after tax and exceptional items was Rs. 336.22 million.

Outlook and guidance

• FY27 revenue guidance maintained at INR 2,200–2,300 crore, with EBITDA margin expected at 10–11%.

• Margins expected to improve to double digits by Q3, with H2 margins projected at 13–15%.

• FY28 normalized EBITDA margin anticipated at 12–14%.

• Segment realignment and insurance recoveries are expected to support future performance.

• Q2 expected to show improvement across all segments, with positive EBITDA in aroma and performance chemicals.